Shares of VIVUS, Inc.(NASDAQ:VVUS) fell by $3.16 or
21.14% to $11.79 in the morning session as the company posted a wider than
estimated loss in the Q3.
Vivus posted a net loss of $40.40 million or $0.40
cents per share in comparison to $8.63 million 0r $0.10 cents per share for the
last year.
Is It the Right Time
to Buy VVUS after Today’s Slump? We Have Special Report Here
The biopharmaceutical company dedicated to the
development and commercialization of novel therapeutic products, primarily
attributed increased selling, general and administrative expenses related to
pre-commercialization and commercialization activities for Qsymia to be the
reasons for increase in net loss.
The start-up costs associated with the post-approval
studies for Qsymia and STENDRA led to increase in research and development
expenses.
Prescriptions shipped from certified pharmacies to
patients helped the company to recognize net product revenue of $41 thousand
for the third quarter.
Stocks of Express Scripts Holding
Company(NASDAQ:ESRX) fell by $8.70 or 13.84% to $54.18 in the morning session
as the company deemed the analyst forecast for year 2013 as "overly
aggressive," which casted doubts as to how well the company is integrating
its $29 billion purchase of Medco Health Solutions Inc.
How Should Investors
Trade ESRX After Today’s Slump? Get Free Trend Analysis Here
Excluding special items the third quarter earnings
were $1.02, arise by 29% in comparison to last year, which beats analyst
expectation of 99 cents per share according to Thomson Reuters I/B/E/S.
Further net income rose by 21% to $391.4 million as
compared to last year. Revenue increased by 133% to $27 billion. Claims rose
116 percent to 398.6 million.
Raising the lower end of its forecast range for 2012
earnings by 5 cents Express Scripts projects full-year profit this year of $3.65
to $3.75 a share.
Analyst projects $4.49 a share in 2013, according to
Thomson Reuters I/B/E/S. But the company said the analyst forecast to be too
aggressive.
No comments:
Post a Comment